4.7 Article

Medicinal chemistry of P2 and adenosine receptors: Common scaffolds adapted for multiple targets

期刊

BIOCHEMICAL PHARMACOLOGY
卷 187, 期 -, 页码 -

出版社

PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.bcp.2020.114311

关键词

P2X receptor; P2Y receptor; Adenosine receptor; Purinergic agonist; Purinergic antagonist; Scaffold

资金

  1. NIDDK Intramural Research Program [ZIADK31116, ZIADK31117, ZIADK31126]
  2. Deutsche Forschungsgemeinschaft [SFB1328, FOR2372, GRK1873]

向作者/读者索取更多资源

This review paper explores the historical origins of P2 receptors and adenosine receptor ligands, emphasizing the versatility of common chemical scaffolds for multiple receptor targets. By analyzing structure activity relationships, selective receptor subtype targeting can be achieved, leading to potential therapeutic applications in various diseases.
Prof. Geoffrey Burnstock originated the concept of purinergic signaling. He demonstrated the interactions and biological roles of ionotropic P2X and metabotropic P2Y receptors. This review paper traces the historical origins of many currently used antagonists and agonists for P2 receptors, as well as adenosine receptors, in early attempts to identify ligands for these receptors ? prior to the use of chemical libraries for screening. Rather than presenting a general review of current purinergic ligands, we focus on common chemical scaffolds (privileged scaffolds) that can be adapted for multiple receptor targets. By carefully analyzing the structure activity relationships, one can direct the selectivity of these scaffolds toward different receptor subtypes. For example, the weak and non-selective P2 antagonist reactive blue 2 (RB-2) was derivatized using combinatorial synthetic approaches, leading to the identification of selective P2Y2, P2Y4, P2Y12 or P2X2 receptor antagonists. A P2X4 antagonist NC-2600 is in a clinical trial, and A3 adenosine agonists show promise, for chronic pain. P2X7 antagonists have been in clinical trials for depression (JNJ-54175446), inflammatory bowel disease (IBD), Crohn?s disease, rheumatoid arthritis, inflammatory pain and chronic obstructive pulmonary disease (COPD). P2X3 antagonists are in clinical trials for chronic cough, and an antagonist named after Burnstock, gefapixant, is expected to be the first P2X3 antagonist filed for approval. We are seeing that the vision of Prof. Burnstock to use purinergic signaling modulators, most recently at P2XRs, for treating disease is coming to fruition.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据